These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17090814)

  • 1. Bolus-only glycoprotein IIb/IIIa inhibitor revisited.
    Agahtehrani A; Dangas GD
    J Invasive Cardiol; 2006 Nov; 18(11):527. PubMed ID: 17090814
    [No Abstract]   [Full Text] [Related]  

  • 2. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
    De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS
    Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
    Coto H
    J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ; Kereiakes DJ
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 7. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Störk T; Fröhlich E; Möckel M
    Lancet; 2001 Dec; 358(9297):1996-7. PubMed ID: 11747950
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab: a review and update for clinicians.
    Mazzaferri EL; Young JJ
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):609-18. PubMed ID: 18510478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function.
    Pellicori P; Torromeo C; Barillà F; Mangieri E; Evangelista A; Truscelli G; Costanzo P; Hoye A; Wong K
    Cardiol J; 2013; 20(3):310-7. PubMed ID: 23788306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    Tcheng JE; Campbell ME
    J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycoprotein Wars and PIECE activists.
    Goldberg S
    J Invasive Cardiol; 2003 Jun; 15(6):324-5. PubMed ID: 12777671
    [No Abstract]   [Full Text] [Related]  

  • 15. "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship.
    Kandzari DE; Tcheng JE; Harrington RA; Sketch MH
    J Invasive Cardiol; 2000 Oct; 12(10):502-4. PubMed ID: 11022208
    [No Abstract]   [Full Text] [Related]  

  • 16. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
    Roffi M; Mukherjee D
    Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between glycoprotein IIb/IIIa blockade and distal protection device for the restoration of myocardial perfusion during percutaneous coronary intervention for acute myocardial infarction.
    Mak KH; Phay C; Wong A; Kwok V; Tan KS; Lau KW; Koh TH
    J Invasive Cardiol; 2004 Dec; 16(12):694-8. PubMed ID: 15596872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.